Besides, more patients had actionable variants of level 3 than level 4 (39.53% vs 4.65%), as nearly a quarter of the cervical cancer patients had actionable of alterations in PIK3CA, which may confer sensitivity to the PI3K or mTOR inhibitors. The gene discussed is PIK3CA; the disease is cervical cancer.